tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Sino Biopharmaceutical Advances Respiratory Drug Portfolio with Promising Study Results

Story Highlights
  • Sino Biopharmaceutical is advancing respiratory drugs with promising study results.
  • TQC3403 is set to be China’s first marketed generic for umeclidinium bromide and vilanterol.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Sino Biopharmaceutical Advances Respiratory Drug Portfolio with Promising Study Results

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Sino Biopharmaceutical ( (HK:1177) ) just unveiled an announcement.

Sino Biopharmaceutical Limited announced the presentation of data from four studies on their respiratory drugs at the 2025 European Respiratory Society Annual Meeting. The studies include TQC3721, a PDE3/4 inhibitor with bronchodilatory and anti-inflammatory effects, which has been granted Breakthrough Therapy Designation in China and is in Phase III trials. TQC2731, a TSLP monoclonal antibody, is progressing rapidly in trials for asthma and other inflammatory diseases. TQC3403, a combination of umeclidinium bromide and vilanterol, is set to become the first marketed generic version in China, expected by 2026. These developments highlight Sino Biopharmaceutical’s strong positioning in the respiratory drug market and potential impact on stakeholders.

The most recent analyst rating on (HK:1177) stock is a Buy with a HK$9.17 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a company in the pharmaceutical industry, focusing on the development and production of innovative medicines. The company is known for its work in respiratory and autoimmune diseases, with a market focus on China.

YTD Price Performance: 157.24%

Average Trading Volume: 184,018,982

Technical Sentiment Signal: Buy

Current Market Cap: HK$146.1B

Learn more about 1177 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1